1. Introduction

Biotechnology Antitrust Regulation in Russia refers to the legal framework governing competition, monopolistic practices, market dominance, mergers, patent exploitation, licensing arrangements, pricing policies and anti-competitive agreements in the biotechnology and pharmaceutical industries.

The biotechnology sector includes several commercially important activities:

Genetic engineering and genome-editing technologies.

Pharmaceutical biotechnology and biologic medicines.

Vaccines, antibodies and biosimilars.

Stem-cell research and regenerative medicine.

Biotechnology manufacturing and laboratory services.

Genetic testing and diagnostic technologies.

Biological research materials and biopharmaceutical products.

Biotechnology patents, research licensing and technology transfers.

Russia regulates competition in these markets primarily through Federal Law No. 135-FZ of 26 July 2006, On Protection of Competition.

The principal enforcement authority is the Federal Antimonopoly Service (FAS Russia).

An important distinction must be made: Russia does not have a separate comprehensive antitrust statute exclusively for biotechnology. Instead, general competition legislation applies to biotechnology companies, pharmaceutical manufacturers, research institutions, distributors, patent holders and other market participants.

Pharmaceutical competition cases are particularly important because they provide judicial guidance for biologics, biosimilars, biotechnology-derived medicines and related intellectual-property disputes.

2. Legal Framework Governing Biotechnology Competition

The principal legislation includes the following:

These laws operate together.

For example, a biotechnology company may possess a valid patent under the Civil Code but still face antitrust scrutiny if its commercial conduct violates competition law.

Similarly, a pharmaceutical company may have regulatory approval for a biological medicine, but regulatory approval does not automatically authorize anti-competitive distribution arrangements.

3. Prohibition of Abuse of Dominant Market Position

Article 10 of Federal Law No. 135-FZ prohibits the abuse of a dominant position.

This provision is particularly significant in biotechnology because certain companies may control:

Patented biological medicines.

Exclusive manufacturing technologies.

Essential biological materials.

Specialised genetic-testing platforms.

Proprietary laboratory equipment.

Distribution networks for specialised medicines.

Dominance itself is not necessarily unlawful. The violation occurs when a dominant company abuses its market position in a manner prohibited by law.

Examples of potentially unlawful conduct include:

Charging monopolistically high prices for essential biological medicines.

Unjustifiably refusing to supply distributors.

Imposing discriminatory commercial conditions.

Creating artificial barriers to competing biosimilar manufacturers.

Restricting access to essential biotechnology products.

Imposing economically unjustified contractual conditions.

Example:

Suppose a Russian pharmaceutical biotechnology company is the only supplier of a particular biologic medicine.

It increases prices substantially without adequate economic justification and refuses to supply independent distributors.

The FAS may investigate whether the company occupies a dominant position and whether its conduct violates Article 10.

The investigation would consider market definition, substitutability, barriers to entry, market power and the economic justification for the conduct.

4. Anti-Competitive Agreements and Cartels

Article 11 of Federal Law No. 135-FZ prohibits agreements between competing businesses that restrict competition.

This is important in biotechnology because research and pharmaceutical markets frequently involve cooperation between manufacturers, laboratories, distributors and suppliers.

Potentially prohibited arrangements include:

A. Price-fixing agreements

Two biotechnology manufacturers agree to maintain artificially high prices for biological medicines.

B. Market allocation

Competing pharmaceutical companies agree that one will supply vaccines in one region while another controls a different region.

C. Bid-rigging

Biotechnology suppliers coordinate their bids in government tenders for vaccines, laboratory equipment or biological products.

D. Production restrictions

Competing manufacturers agree to reduce the production of essential medicines to increase market prices.

E. Collective refusal to deal

Competing suppliers coordinate their refusal to supply a particular biotechnology distributor or purchaser.

Cartel arrangements are particularly serious because they may attract administrative penalties and, where the statutory criminal elements are established, criminal liability.

Case Law 1: Pharmstandard and ROSTA Cartel Case

Case No.: A40-94475/2012.

FAS Decision: No. 1-11/202-11.

Important judicial decision: 22 April 2013.

Supreme Court ruling concerning the fine: 18 February 2016, No. 305-AD14-3104.

Facts: Pharmstandard and ROSTA challenged a FAS decision concerning an agreement to maintain auction prices.

Legal issue: Whether coordination between pharmaceutical market participants to maintain auction prices violated competition law.

Decision: The cassation court rejected the companies' challenge to the FAS decision. The Supreme Court subsequently upheld the judicial acts concerning the administrative fine of approximately RUB 201.38 million against Pharmstandard.

Legal significance: The case demonstrates that pharmaceutical companies cannot coordinate bidding or pricing strategies to undermine competition in public procurement.

Biotechnology application: The same principles apply to companies supplying vaccines, biosimilars, laboratory reagents and biotechnology-derived medicines.

Goya Group+1

5. Unfair Competition in Biotechnology

Articles 14.1–14.8 of Federal Law No. 135-FZ regulate different forms of unfair competition.

Article 14.5 is particularly important for intellectual-property-related unfair competition.

Biotechnology businesses may face legal scrutiny for:

Unlawfully using another company's patented technology.

Misappropriating confidential laboratory information.

Misleading consumers about the biological origin of medicines.

Using another company's commercial reputation.

Introducing competing products through unlawful exploitation of protected intellectual property.

Misrepresenting the quality or characteristics of biosimilars.

An important distinction exists between ordinary patent infringement and unfair competition. Not every patent infringement automatically constitutes an antitrust violation. The relevant statutory elements of unfair competition must also be established.

Case Law 2: Axitinib Patent and Unfair Competition Dispute

Case No.: A40-264483/2024.

FAS decision: 4 October 2024.

Moscow Arbitration Court proceedings: 2025.

Supreme Court review: 2026.

Facts: The dispute concerned the introduction of a generic version of axitinib, a cancer medicine, before the expiry of patent protection.

The FAS considered the introduction of the generic product to constitute unfair competition under Article 14.5.

Initial judicial developments: In March 2025, the Moscow Arbitration Court annulled the FAS decision. The appellate court also ruled against the FAS in July 2025.

Subsequent development: On 1 July 2026, the Presidium of the Russian Supreme Court approved Review of Case Law No. 2 (2026), addressing this dispute under Item 23.

The Supreme Court confirmed that introducing a generic medicine before patent expiry without the patent owner's consent may constitute unfair competition under Article 14.5. It also clarified that direct competition between the patent holder and the alleged infringer need not necessarily be demonstrated where the patent holder's economic interests are harmed.

Legal significance: This is a significant development for biotechnology-derived medicines, biosimilars and pharmaceutical manufacturers. Marketing authorisation does not itself eliminate the need to respect applicable patent rights.

en.khp.legal+1

6. Patent Rights and Biotechnology Competition

Patent protection is fundamental to biotechnology innovation.

A biotechnology company may hold patents relating to:

Gene-editing processes.

Recombinant DNA technologies.

Monoclonal antibodies.

Vaccine manufacturing.

Biological drug formulations.

Diagnostic technologies.

Cell-culture processes.

Therapeutic proteins.

The Russian Civil Code, particularly Part IV, establishes the framework for intellectual-property protection.

However, patent rights and competition law must be considered together.

Article 10(4) and Article 11(9) of Federal Law No. 135-FZ contain important qualifications concerning agreements and conduct involving exclusive rights to intellectual-property objects.

These provisions should not be interpreted as a blanket immunity for every commercial practice associated with patents.

For example, a patent holder's exclusive right to manufacture an invention does not automatically justify every refusal to supply, discriminatory commercial arrangement or other independent anti-competitive practice.

Case Law 3: Novartis Pharma – Lapatinib Pricing Dispute

Period: 2017–2018.

Relevant provision: Article 10(1) of Federal Law No. 135-FZ.

Facts: Novartis Pharma was investigated concerning the pricing of lapatinib, a patented oncology medicine.

The FAS concluded that commercially unjustified distributor bonuses and discounts contributed to a monopolistically high price. The reported increase was approximately 35% per package.

FAS decision: The regulator ordered the company to eliminate the identified violation.

Judicial outcome: The Russian judicial system did not support the FAS decision.

Legal significance: The dispute illustrates the difficulty of distinguishing legitimate patent-based commercial freedom from abusive pricing practices. It also demonstrates that a regulator must establish the legal and economic elements of an abuse rather than merely rely on the existence of high prices.

Biotechnology application: Similar questions may arise where a manufacturer controls a patented monoclonal antibody, a specialised vaccine or a unique biological therapy.

UNCTAD+1

7. Refusal to Supply Biotechnology Products

A dominant biotechnology company may not arbitrarily refuse to supply essential products when the refusal violates Article 10.

This issue is especially important where a company controls:

Essential medicines.

Exclusive biological manufacturing facilities.

Specialised pharmaceutical ingredients.

Essential laboratory materials.

Products required for public healthcare programmes.

Case Law 4: TEVA and Biotek – Copaxone Supply Dispute

Facts: In 2010, TEVA entered into a five-year agreement with Biotek concerning the supply, storage, secondary packaging, distribution and promotion of Copaxone, a medicine used to treat multiple sclerosis.

In 2012, TEVA established its own Russian office and began participating directly in government procurement. It allegedly disregarded its existing contractual arrangements and avoided concluding supply agreements with Biotek.

Legal issue: Whether the refusal to supply the medicine violated Article 10 despite TEVA's reliance on intellectual-property protections.

Decision: The FAS found an antimonopoly violation. The Supreme Court of the Russian Federation supported the FAS decision.

Legal significance: Intellectual-property rights cannot automatically be used to justify conduct that independently violates competition legislation.

Biotechnology application: This principle is relevant to exclusive suppliers of biological medicines, genetic-testing materials, specialised research products and other biotechnology-related goods.

UNCTAD+1

8. Pharmaceutical Distribution and Exclusive Agreements

Biotechnology products frequently reach consumers through complicated distribution systems.

A manufacturer may appoint:

Exclusive distributors.

Regional pharmaceutical wholesalers.

Specialised cold-chain logistics companies.

Biological product packaging companies.

Medical supply intermediaries.

These agreements can be commercially legitimate. However, they may attract antitrust scrutiny when they restrict market access or facilitate price manipulation.

Case Law 5: Sprycel Distribution Dispute

- Case No.: A40-27528/2019.

Facts: A company complained to the FAS about an alleged anti-competitive agreement between a manufacturer and packaging companies concerning the distribution of Sprycel.

The complainant argued that the arrangements restricted the number of entities able to purchase and distribute the medicine and helped maintain higher prices.

Legal development: The FAS initially declined to initiate proceedings. The appellate court considered that the arrangements could create obstacles to free purchasing and restrict competition, and required the authority to reconsider the matter.

Legal significance: Distribution and packaging agreements cannot be assessed solely as ordinary commercial contracts. Their practical effects on competition must also be examined.

Biotechnology application: Similar scrutiny may arise when manufacturers restrict access to biological medicines, vaccines or specialised diagnostic products through exclusive packaging and distribution arrangements.

Юридическая фирма БРЭЙС | BRACE Law Firm+1

9. Merger Control and Biotechnology Acquisitions

Biotechnology markets frequently involve mergers, acquisitions, joint ventures and strategic investments.

For example:

A foreign biotechnology company acquires a Russian vaccine manufacturer.

A pharmaceutical corporation purchases a biosimilar producer.

Two genetic-testing companies combine their operations.

A biotechnology laboratory acquires a competitor's research facilities.

A multinational pharmaceutical company acquires a domestic biological-drug manufacturer.

Articles 27–29 of Federal Law No. 135-FZ establish important requirements concerning economic concentration and merger control.

The FAS may examine whether a transaction could substantially restrict competition.

Its assessment may consider:

Existing market shares.

Barriers to entry.

Control over essential technologies.

Availability of alternative biological products.

Effects on research and development.

Access to distribution networks.

Potential exclusion of competing manufacturers.

Case Law 6: Ranbaxy Acquisition of Biosynthesis (2016)

Facts: The FAS approved Ranbaxy's acquisition of 100% of Biosynthesis OJSC, a Russian pharmaceutical manufacturer.

Regulatory conditions: The FAS imposed conditions requiring the purchaser to honour existing contracts with counterparties and avoid unjustified reductions in production and sales.

It also required the development and publication of a document governing commercial interactions with counterparties.

Legal significance: The case demonstrates how Russian merger control can protect commercial relationships and supply continuity when pharmaceutical businesses change ownership.

Biotechnology application: Similar conditions may be relevant when acquiring vaccine manufacturers, biotechnology production facilities and manufacturers of biological medicines.

OECD ONE+1

10. Biotechnology Pricing and Market Regulation

Pricing is an important component of Russian pharmaceutical antitrust enforcement.

The FAS investigates whether dominant manufacturers establish monopolistically high prices or engage in discriminatory pricing practices.

Special attention is given to medicines included in Russia's Essential Drugs List.

The following case is relevant.

Case Law 7: Zambon-Pharma – Fluimucil-Antibiotic IT

Period investigated: 2023 to the first quarter of 2025.

Facts: The FAS investigated Zambon-Pharma concerning the pricing of Fluimucil-antibiotic IT, which contains thiamphenicol glycinate acetylcysteinate.

The company was reportedly the sole importer of the medicine and occupied a dominant position in a market without interchangeable alternatives.

The investigation identified a 46% increase in the ex-factory price.

Regulatory outcome: According to the October 2026 antitrust review, the FAS ordered a payment of RUB 418.8 million to the federal budget and required the establishment of an economically justified price.

Legal significance: The case illustrates the application of dominance and excessive-pricing principles to specialised pharmaceutical products.

Biotechnology application: Similar principles may apply to patented biological medicines and specialised biotechnology products where the relevant market has no effective substitutes.

Алруд+1

11. Public Procurement and Biotechnology Competition

The Russian government purchases substantial quantities of pharmaceutical and medical products.

Biotechnology companies may participate in tenders for:

Vaccines.

Insulin products.

Antibiotics.

Biological medicines.

Laboratory testing materials.

Medical diagnostic equipment.

Genetic-testing services.

Federal Laws No. 44-FZ and No. 223-FZ operate alongside the Competition Law.

The FAS may investigate:

Collusive tender participation.

Artificially inflated bids.

Agreements between competing suppliers.

Unjustified exclusion of bidders.

Manipulation of tender specifications.

Agreements between procurement organisers and participating companies.

In Case No. A55-30553/2017, pharmaceutical suppliers were investigated for alleged coordination across more than 400 auctions. Evidence included common IP addresses, overlapping application preparation and financial relationships.

The case illustrates how digital and commercial evidence can establish collusion in pharmaceutical procurement.

Юридическая фирма БРЭЙС | BRACE Law Firm+1

12. Antitrust Regulation of Biosimilars

Biosimilars are biological medicines highly similar to an already authorised reference biological medicine.

They are important because they may increase competition and expand access to biological treatments.

However, biosimilar manufacturers face several legal challenges.

Major competition issues include:

Patent disputes involving reference biological medicines.

Unjustified restrictions on access to manufacturing technology.

Exclusive distribution arrangements.

Misleading claims about product equivalence.

Anti-competitive pricing strategies.

Unlawful exploitation of confidential manufacturing information.

Agreements designed to delay market entry.

Russian competition law must balance patent protection with the preservation of competitive markets.

A biosimilar manufacturer cannot automatically rely on regulatory approval as permission to use another company's protected invention.

Equally, an originator cannot assume that patent ownership gives it unrestricted freedom to engage in anti-competitive commercial practices.

The Axitinib Supreme Court review is especially relevant to this balance.

13. Enforcement Powers and Penalties

The FAS has significant enforcement powers under Federal Law No. 135-FZ.

Its regulatory activities include:

Investigating suspected anti-competitive agreements.

Examining market dominance.

Issuing warnings and compliance orders.

Investigating unfair competition.

Reviewing mergers and acquisitions.

Examining public procurement violations.

Imposing administrative sanctions through the applicable legal procedures.

The principal liability provisions include:

Penalties may include turnover-based administrative fines, orders to eliminate violations and, in appropriate cases, criminal liability for responsible individuals.

Companies may also challenge FAS decisions before the Russian arbitration courts.

Russian Federation+2

14. Challenges in Biotechnology Antitrust Regulation

Russia's biotechnology industry faces several competition-related challenges.

A. Patent monopolies

Exclusive patent rights can create substantial market power, particularly where a medicine has no effective substitute.

B. High research and development costs

Biotechnology research requires significant investment, specialised equipment and technical expertise.

C. Biosimilar market entry

Patent disputes and regulatory requirements may complicate the introduction of competing biological medicines.

D. Access to biological materials

Exclusive control over specialised biological samples, cell lines and research materials can create potential competition concerns.

E. Technology licensing

Unreasonable licensing restrictions may discourage independent research and commercial innovation.

F. International competition

Foreign investment restrictions, technology-transfer arrangements and cross-border intellectual-property disputes can affect competition in the Russian biotechnology market.

G. Pharmaceutical supply security

A company controlling an essential biological medicine may possess significant bargaining power over distributors and healthcare purchasers.

These challenges require competition authorities to consider both the protection of innovation and the availability of competing products.

15. Compliance Obligations for Biotechnology Companies

Biotechnology businesses operating in Russia should establish comprehensive antitrust compliance programmes.

Recommended measures include:

Particular attention should be given to agreements involving competitors, research consortia, biotechnology licensing and exclusive distribution arrangements.

16. Important Case Laws: Consolidated Overview

The following decisions and proceedings provide useful guidance for studying Russian biotechnology-related competition law.

An important qualification: these are principally pharmaceutical-sector precedents, not judgments specifically about gene editing, stem cells or biotechnology laboratories. Their principles can be relevant to those industries, but their application depends on the facts and statutory requirements of each case.

en.khp.legal+5

17. Conclusion

Biotechnology antitrust regulation in Russia is based primarily on Federal Law No. 135-FZ, supported by intellectual-property, pharmaceutical, procurement and administrative legislation.

The FAS plays a central role in preventing monopolistic conduct, investigating anti-competitive agreements, regulating mergers and protecting market competition.

Three important legal principles emerge from Russian enforcement practice:

Dominance is not automatically unlawful: Abuse of dominant market position is prohibited.

Patent protection is not unlimited commercial immunity: Intellectual-property rights must be distinguished from independent anti-competitive conduct.

Innovation and competition must coexist: Biotechnology companies must protect their inventions while respecting competition rules.

The Axitinib Supreme Court review approved in July 2026 is particularly important because it clarifies the relationship between patent exclusivity and unfair competition in the pharmaceutical market.

Ultimately, Russian antitrust regulation seeks to maintain competition, protect commercial participants and preserve access to important pharmaceutical and biotechnology products.

18. Important Legal Research Sources

For further academic research, the following sources are useful:

UNCTAD – Russian Federation's contribution on pharmaceutical competition law.

Russian Supreme Court – Axitinib case-law review, 2026.

ALRUD – Russian Antitrust Review, October 2026.

BRACE – Antitrust Restrictions in Russian Pharmaceutical Markets.

Pharmstandard Cartel – Judicial Case Archive.

Academic research note: This analysis focuses on the Russian legal framework and pharmaceutical precedents relevant to biotechnology. For litigation or legal opinions, the authoritative Russian statutory texts and original court judgments should be consulted, particularly where English translations are unofficial.